製品名:Neopentylamine

IUPAC Name:2,2-dimethylpropan-1-amine

CAS番号:5813-64-9
分子式:C5H13N
純度:98%
カタログ番号:CM117653
分子量:87.17

包装単位 有効在庫 価格(USD) 数量
CM117653-25g in stock ƴƐȯ
CM117653-100g in stock ȖǑǑ
CM117653-500g 1-2 Weeks ƴǑǑƐ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:5813-64-9
分子式:C5H13N
融点:-
SMILESコード:NCC(C)(C)C
密度:
カタログ番号:CM117653
分子量:87.17
沸点:
MDL番号:MFCD00008134
保管方法:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Nitrogen Compounds
Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
Ogsiveo
The FDA has approved Ogsiveo (Nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. The FDA approval of Ogsiveo is based on the results from the Phase 3 DeFi trial. The results showed that Ogsiveo met the primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement over placebo with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). Ogsiveo is an oral, selective, small molecule gamma secretase inhibitorγ. Gamma secretase cleaves multiple transmembrane proteins, including Notch, that are believed to play a role in activating pathways that contribute to growth of desmoid and ovarian granulosa cell tumors.

Related Products